Perceptions and recommendation behaviors of dermatologists for medical cannabis: A pilot survey

Yeroushalmi, Samuel; Nelson, Kamaria; Sparks, Andrew; Friedman, Adam

doi:10.1016/j.ctim.2020.102552

Cited by 8 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 A recent study highlighted that the majority of dermatologists are in favor of medical cannabis and several recommended topical cannabis for dermatologic conditions including atopic dermatitis and psoriasis. 30 Dermatologists in particular though are less likely to recommend medical cannabis due to limited knowledge and experience. 30 This may explain why only 18% of cannabis users received information from primary care providers according to a recent study.…”

Section: Discussionmentioning

confidence: 99%

“…30 Dermatologists in particular though are less likely to recommend medical cannabis due to limited knowledge and experience. 30 This may explain why only 18% of cannabis users received information from primary care providers according to a recent study. 31 Cannabis users who were informed by their physicians had better knowledge of the medical effectiveness of cannabis compared to patients who were informed by other means 31 which also shows tremendous opportunity to educate patients regarding potential dangers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Survey of Topical Cannabis Use in Canada

2021

View full text Add to dashboard Cite

Background Since its legalization in Canada, cannabis use has expanded to include commercially available topical formations. Several scientifically unsupported claims regarding the therapeutic efficacy of topical cannabis are also being made. Developing an understanding of the consumer uses of topical cannabis is important for clinicians to provide appropriate counseling and inform potential areas of therapeutic development. We are examining the prevalence, purpose of use, and sources of information regarding topical cannabis in the Canadian population, with a focus on dermatologic uses. Method A cross-sectional, anonymous electronic, voluntary survey was developed to assess the use of topical cannabis amongst adults in Canada. Results Cannabis was used topically at least once by 24.3% of respondents who started the survey. The commonest form of topical cannabis were creams (26.2%). The most common dermatologic conditions being treated with topical cannabis included atopic dermatitis (25%), acne (19%), and anti-aging (16%); for non-dermatologic conditions, common uses were for joint stiffness or tendonitis (30%) and headaches and migraines (27%). Topical cannabis was reported to be most effective for joint stiffness and tendonitis, general muscular soreness, headaches, eczema, pruritus, acne, and psoriasis. Most respondents obtained and received information about topical cannabis from dispensaries. Conclusion Canadians use topical cannabis for a broad range of systemic and dermatologic purposes, most of which have limited evidence. Future clinical studies are required to elucidate the therapeutic efficacy and safety of topical cannabis. Dermatologists should screen their patients for topical cannabis use and be aware of the limited evidence of therapeutic potential.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A Survey of Topical Cannabis Use in Canada

2021

View full text Add to dashboard Cite

show abstract

“…In terms of the cannabinoids' preferred prescribing route, topical administration has additional promises in its prescribability. A systematic review published by Yeroushalmi et al performed a pilot survey to determine the willingness of dermatologists to recommend medical cannabis, and 75% of dermatologists recommended topical formulations [76]. This route is likely preferred due to its convenience, without the concerns of the psychoactive impacts of systemic absorption, as well as the high safety profile of topical administration routes [77].…”

Section: Delivery Routes and Bioavailability Of Cannabinoidsmentioning

confidence: 99%

The Transdermal Delivery of Therapeutic Cannabinoids

et al. 2022

View full text Add to dashboard Cite

Recently, several studies have indicated an increased interest in the scientific community regarding the application of Cannabis sativa plants, and their extracts, for medicinal purposes. This plant of enormous medicinal potential has been legalised in an increasing number of countries globally. Due to the recent changes in therapeutic and recreational legislation, cannabis and cannabinoids are now frequently permitted for use in clinical settings. However, with their highly lipophilic features and very low aqueous solubility, cannabinoids are prone to degradation, specifically in solution, as they are light-, temperature-, and auto-oxidation-sensitive. Thus, plant-derived cannabinoids have been developed for oral, nasal-inhalation, intranasal, mucosal (sublingual and buccal), transcutaneous (transdermal), local (topical), and parenteral deliveries. Among these administrations routes, topical and transdermal products usually have a higher bioavailability rate with a prolonged steady-state plasma concentration. Additionally, these administrations have the potential to eliminate the psychotropic impacts of the drug by its diffusion into a nonreactive, dead stratum corneum. This modality avoids oral administration and, thus, the first-pass metabolism, leading to constant cannabinoid plasma levels. This review article investigates the practicality of delivering therapeutic cannabinoids via skin in accordance with existing literature.

show abstract

“… 1 Increases in access to cannabinoid-derived medical products parallel the interest of patients and dermatologists regarding potential therapeutic uses for a variety of skin conditions. 2 , 3 Connecticut is the only state currently listing psoriasis and psoriatic arthritis as indications for medical cannabis, though 7 states include arthritis. However, the scientific literature validating the efficacy and safety of cannabinoids for common chronic inflammatory skin diseases, such as psoriasis, is sparse.…”

mentioning

confidence: 99%

“…Importantly, 100% of respondents expressed interested in learning about the potential uses of medical cannabis, very much in parallel with past studies which found an overwhelming majority of dermatologists surveyed also wanted more education on medical cannabis applications (91% to 93%). 2 , 5…”

mentioning

confidence: 99%